Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

IV Treatment May Lower Risk of Dying From Bacterial Meningitis

30.09.2010
New research shows that an intravenous (IV) treatment may cut a person’s risk of dying from bacterial meningitis. The research is published in the September 29, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology. The treatment is called dexamethasone.

“Using this treatment in people infected with meningitis has been under debate because in a few large studies it was shown to be ineffective,” said study author Diederik van de Beek, MD, PhD, with the Academic Medical Center, University of Amsterdam in the Netherlands and a member of the American Academy of Neurology. “Our results provide valuable evidence suggesting that dexamethasone is effective in adult cases of bacterial meningitis and should continue to be used.”

Bacterial meningitis is a condition that causes membranes in the brain and spinal cord to become inflamed. The disease can be deadly, or result in hearing loss, brain damage and learning disabilities. Pneumococcal meningitis is the most common and severe form of bacterial meningitis. It is estimated that about 25 to 30 percent of people die from the disease.

For the study, researchers evaluated 357 Dutch people age 16 or older with pneumococcal meningitis between 2006 and 2009. Of those, 84 percent were given dexamethasone through an IV with or before the first dose of antibiotics. The results were compared to an earlier study of 352 people treated for bacterial meningitis in 1998-2002, before Netherlands guidelines recommended using dexamethasone. In that study, only three percent of the people were given dexamethasone.

In both studies, participants were assessed on a rating scale of one to five. A score of one was given for death, two for coma, three for severe disability, four for moderate disability and five for mild or no disability. In the later study, 39 percent had an “unfavorable outcome,” or a score of four or lower on the scale, compared to 50 percent in the earlier study group.

The study found that the rate of death for those who were given dexamethasone was 10 percent lower than in those in early study group. The rates of hearing loss were also nearly 10 percent lower for those in the later study group.

Symptoms of bacterial meningitis are neck stiffness, fever and an altered mental state. These are also symptoms of viral meningitis, which is more common, much less serious and was not the focus of this study. Bacterial meningitis is a medical emergency and is diagnosed by culturing bacteria from the spinal fluid or by observing changes in the spinal fluid which indicate the presence of bacteria. Bacterial meningitis must always be treated with antibiotics in addition to medications like dexamethasone, which is a medication of the glucocorticosteroid class of drugs and may be used for bacterial meningitis.

The study was supported by the Netherlands Organization for Health Research and Development and the Academic Medical Center, University of Amsterdam.

The American Academy of Neurology, an association of more than 22,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer’s disease, narcolepsy, and stroke.

For more information about the American Academy of Neurology, visit http://www.aan.com.

VIDEO: http://www.youtube.com/AANChannel
TEXT: http://www.aan.com/press
TWEETS: http://www.twitter.com/AANPublic

Rachel L. Seroka | American Academy of Neurology
Further information:
http://www.aan.com

More articles from Studies and Analyses:

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>